Vorolanib by Betta Pharmaceuticals for Thymic Carcinoma: Likelihood of Approval

Vorolanib is under clinical development by Betta Pharmaceuticals and currently in Phase II for Thymic Carcinoma.

Protocol Optimizing Meds for T2D and CVD Pushed Beyond Cardiology Alone

SAN DIEGO — Cardiovascular medications were better optimized for patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) following a multifaceted intervention involving

June 28, 2023

Young people may be more susceptible to the effects of elevated blood cholesterol and hypertension

Young people may be more susceptible to the effects of the risk factors for developing atherosclerosis. According to a study carried out at the Centro

November 20, 2023

Do Ultraprocessed Foods Increase Lupus Risk for Women?

Among women followed for upwards of 25 years, those who ate relatively large amounts of “ultraprocessed” foods — such as soft drinks, frozen pizzas, and

July 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.